- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Praxis Precision Medicines: Raymond James sieht Kurspotenzial von über 150 % | 1 | Investing.com Deutsch | ||
| Do | Raymond James initiates Praxis Precision Medicines stock coverage with Strong Buy | 1 | Investing.com | ||
| Di | H.C. Wainwright reiterates Praxis Precision stock rating on trial data | 8 | Investing.com | ||
| Mo | Praxis Precision Medicines, Inc. - 8-K, Current Report | - | SEC Filings | ||
| Mo | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy | 75 | GlobeNewswire (Europe) | Elsunersen demonstrated placebo-adjusted seizure reduction from baseline of 77% (p=0.015) 71% of elsunersen-treated patients achieved >50% seizure reduction by period 6, with sustained benefit observed... ► Artikel lesen | |
| 02.04. | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| PRAXIS PRECISION MEDICINES Aktie jetzt für 0€ handeln | |||||
| 30.03. | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs | 273 | GlobeNewswire (Europe) | FDA assigned PDUFA target action date of September 27, 2026 BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous... ► Artikel lesen | |
| 09.03. | BTIG reiterates Buy on Praxis Precision Medicines stock at $843 | 5 | Investing.com | ||
| 04.03. | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 20.02. | Praxis Precision Medicine Analysts Raise Their Forecasts After Q4 Results | 6 | Benzinga.com | ||
| 19.02. | Earnings call transcript: Praxis Precision verfehlt EPS-Prognose für Q4 2025 | 14 | Investing.com Deutsch | ||
| 19.02. | Truist reiterates Praxis Precision Medicines stock rating on pricing potential | 14 | Investing.com | ||
| 19.02. | Praxis Precision Medicines, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 19.02. | Praxis Precision Medicines, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 19.02. | Praxis Precision Medicines, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.02. | Praxis Precision Medicines GAAP EPS of -$3.50 misses by $0.40 | 4 | Seeking Alpha | ||
| 19.02. | Earnings Breakdown: Praxis Precision Medicine Q4 | 2 | Benzinga.com | ||
| 19.02. | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results | 1.027 | GlobeNewswire (Europe) | Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S.... ► Artikel lesen | |
| 19.02. | Praxis Precision Medicines, Inc. (PRAX) Gains Analyst Confidence With Ulixacaltamide | 5 | Insider Monkey | ||
| 18.02. | Praxis Precision Medicines Q4 2025 Earnings Preview | 1 | Seeking Alpha |
1 2 3 4 5 Weiter >>
126 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 4,536 | +0,22 % | Evotec-Aktie: Neuzugang könnte neue Hoffnungen wecken | Die Evotec-Aktie blieb in der schwachen Phase der Börsen stabil und konnte sich entgegen dem Trend leicht erholen. Am Donnerstag ging sie mit einem Gewinn von +2,2% aus dem Handel und steht bei rund... ► Artikel lesen | |
| QIAGEN | 35,035 | +0,01 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| MODERNA | 43,730 | -0,23 % | Moderna, Inc.: Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 | CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010... ► Artikel lesen | |
| AMGEN | 306,05 | +0,72 % | Amgen: Phase 3 Trial Of TEPEZZA Meets Primary And Key Secondary Endpoints | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced positive topline results from a Phase 3 trial of TEPEZZA administered by subcutaneous injection via an on-body injector in participants with... ► Artikel lesen | |
| NOVAVAX | 7,330 | +0,55 % | Activist investor revives campaign to overhaul Novavax board | ||
| BIOGEN | 150,76 | -0,37 % | Weekly Buzz: ARS Pharmaceuticals Gains FDA Nod; Novo Nordisk received FDA approval for Awiqli; EU Expands Kerendia Label; Eli Lilly Acquires Centessa Pharmaceuticals; Biogen Snaps Up Apellis Pharmaceuticals | BASEL (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S., EU, and China, acquisitions, a few key trial goal misses and positive clinical trial data readouts... ► Artikel lesen | |
| ILLUMINA | 105,18 | -0,45 % | Illumina Expands Collaboration With Labcorp To Advance Precision Oncology | SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), Wednesday announced an expanded collaboration with Labcorp to advance precision oncology through innovative applications of next-generation sequencing... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 44,500 | +0,63 % | Quant ratings on Cathie Wood's top holdings: TSLA, CRSP, AMD, and TEM | ||
| OCUGEN | 1,640 | +1,74 % | Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease | GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,921 | +1,10 % | What's Going On With Inovio Pharmaceuticals Stock On Tuesday? | ||
| INTELLIA THERAPEUTICS | 11,440 | -3,21 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| COSCIENS BIOPHARMA | 1,740 | -0,57 % | Cosciens Biopharma Inc: Cosciens Biopharma does not say why shares are spiking | ||
| EDITAS MEDICINE | 2,460 | 0,00 % | Editas Medicine, Inc. - 8-K, Current Report | ||
| BIOCRYST PHARMACEUTICALS | 8,396 | -0,64 % | BioCryst Pharmaceuticals, Inc.: BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer | - Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval - RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 48,060 | -0,12 % | FDA Expands BioMarin's PALYNZIQ Approval To Include Pediatric PKU Patients Ages 12 And Up | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced Friday that the U.S. Food and Drug Administration has approved the company's supplemental Biologics License Application for... ► Artikel lesen |
PRAXIS PRECISION MEDICINES INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,24 (+0,08 %) liegt der Kurs bei 319,86 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PRAXIS PRECISION MEDICINES INC finden Sie auf Wallstreet Online.